Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

Surgical Infections

Volumn 6, Issue 3, 2005, Pages 283-295

  Lee, Su Young ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; LINEZOLID; METICILLIN; METRONIDAZOLE; NEW DRUG; ORITAVANCIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINUPRISTIN; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; UREIDOPENICILLIN; VANCOMYCIN;

ABSCESS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG PROTEIN BINDING; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 27844534374     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.283     Document Type: Review

References (94)

1. Center for Drug Evaluation and Research (CDER). Uncomplicated and complicated skin and skin structure infections - Developing antimicrobial drugs for treatment. Guidance for Industry. Available:www.fda.gov/cder/guidance/2566dft. pdf, July 1998.
2. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: When the infection is more than skin deep. J Antimicrob Chemother 2004;53: ii37-50.
3. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44:19-23.
4. Centers for Disease Control and Prevention, National Center for Health Statistics. Vital and Health Statistics: Detailed Diagnoses and Procedures. National Hospital Discharge Survey. Hyattsville, MD. U.S. Department of Health and Human Services, 1997.
5. Haley RW, Culver DH, White JW, et al. The nationwide nosocomial infection rate: New need for vital statistics. Am J Epidemiol 1985;121:159-167.
6. Vegas AA, Jodra VM, Garcia ML. Nosocomial infection in surgery wards: A controlled study of increased duration of hospital stays and direct cost of hospitalization. Eur J Epidemiol 1993;9:504-510.
7. Rennie RP, Jones RN, Mutnick AH, and the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003,45:287-293.
8. Hook EW, Hooton TM, Horton CA et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295-297.
9. Sigurdsson AF, Gudmundsson S. Etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989;21:537-542.
10. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-245.
11. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999; 34:65-72.
12. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. CDC Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97-134.
13. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498.
14. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33:S84-S93.
15. Taylor MD, Napolitano LM. Methicillin-resistant Staphylococcus aureus infections in vascular surgery: Increasing prevalence. Surg Infect 2004;5:180-187.
16. Bradley SF, Terpenning MS, Ramsey MA, et al. Methicillin-resistant Staphylococcus aureus: Colonization and infection in a long-term care facility. Ann Intern Med 1991;115:417-422.
17. Mylotte JM, Goodnough S, Tayara A. Antibiotic-resistant organisms among long-term care facility residents on admission to an inpatient geriatrics unit: Retrospective and prospective surveillance. Am J Infect Control 2001;29:139-144.
18. Terpenning MS, Bradley SF, Wan JY, et al. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 1994;42: 1062-1069.
19. Lee YL, Cesario T, Gupta G, et al. Surveillance of colonization and infection with Staphylococcus aureus susceptible or resistant to methicillin in a community skilled-nursing facility. Am J Infect Control 1997;25: 312-321.
20. Bradley S. Methicillin-resistant Staphylococcus aureus in nursing homes. Drugs Aging 1997;18:333-339.
21. Mulhausen PL, Harrell LJ, Weinberger M, et al. Contrasting methicillin-resistant Staphylococcus aureus colonization in Veterans Affairs and community nursing homes. Am J Med 1996;100:24-31.
22. Capitano B, Nicolau DP. Evolving epidemiology and cost of resistance to antimicrobial agents in long-term care facilities. J Am Med Dir Assoc 2003;4:S90-99.
23. Bukharie HA, Abdelhadi MS, Saeed IA, et al. Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn Micobiol Infect Dis 2001;40:1-4.
24. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-710.
25. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003;52:992-996.
26. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2003. MMWR Morb Mortal Wkly Rep 2002;51:566-587.
27. Purcell K, Fergie JE. Exponential increase in community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children. Pediatr Infect Dis J 2002;21:988-989.
28. Akiyama H, Yamasaki O, Tada J, et al. Adherence characteristics and susceptibility to antimicrobial agents of Staphylococcus aureus strains isolated from skin infections and atopic dermatitis. J Dematol Sci 2000;23:155-160.
29. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
30. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:625.
31. Hiramatsu K. Emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998;104:7S-10S.
32. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-766.
33. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-815.
34. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567.
35. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902.
36. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 2004;53: 322-323.
37. Leclercq R, Derlot, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319: 157-161.
38. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29: 95-102.
39. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-929.
40. Paterson DL, Ko WC, Gottberg AV, et al. Antibiotic therapy for Klebsiella penumoniae bacteremia: Implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2003;39:31-37.
41. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended-spectrum β-lactamase. J Antimicrob Chemother 1996;37:203-204.
42. Paterson DL, Ko WC, Von Gottberg JM, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-2212.
43. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
44. Pene C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella peumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998;42: 53-58.
45. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280: 1244-1247.
46. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymixin B and sulbactam. Lancet 1994;344:1329-1332.
47. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-592.
48. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections. Chest 1999;115: 462-474.
49. Ibrahim EH, Sherman G, Ward S, et al. Influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155.
50. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-1423.
51. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
52. Paladino JA. Economic justification of antimicrobial management programs: Implications of antimicrobial resistance. Am J Health Syst Pharm 2000;57:10-12.
53. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin resistant enterococci. Arch Intern Med 2002;162:2223-2228.
54. Capitano B, Leshem A, Nightingale CH, et al. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc 2003;51:10-16.
55. Cosgrove SE, Kaye KS, Eliopoulous GM, et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-190.
56. Boweler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001;14:244-269.
57. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multi-center studies of quinupristin-dalfopristin versus cefazolin, oxacillin, or vancomycin. J Antimicrob Chemother 1999;44:263-273.
58. Hershberger E, Donabedian S, Konstantinou K, et al. Quinupristin-dalfopristin resistance in gram-positive bacteria: Mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-98.
59. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003;22:S172-S177.
60. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-3413.
61. Zyvox (linezolid) package insert. New York: Pfizer, Inc., 2004.
62. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
63. Cubicin (daptomycin) package insert. Lexington, MA: Cubist Pharmaceuticals, 2003.
64. Arbeit RD, Maki D, Tally FP, et al. Safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2004;38:1673-1681.
65. Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-1802.
66. Rezai K, Quinn JP, Hayes R, et al. Emergence of daptomycin resistance and treatment failure in two cases of S. aureus osteomyelitis. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology 2004:K-97a (abst).
67. Goldstein EJC, Citron DM, Merriam DV, et al. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin Infect Dis 2002;35:S119-S125.
68. Invanz (ertapenem) package insert. Whitehouse Station, NJ: Merck & Co. Inc., 2004.
69. Martin SJ, Zeigler DG. Use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004; 5:237-246.
70. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004:38:S341-S345.
71. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-1648.
72. Neuhauser MM, Weinstein RA, Raydman R, et al. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units. JAMA 2003;289:885-888.
73. Barrett JF. Oritavancin. Eli Lilly & Co. Curr Opin Investig Drugs 2001;2:1039-244.
74. Steiert M, Schmitz FJ. Dalbavancin. Curr Opin Investig Drugs 2002;3:229-233.
75. Woodford N. Novel agent for the treatment of resistant gram-positive infections. Expert Opin Investig Drugs 2003;12:117-137.
76. Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J Am Acad Dermatol 2004;50:331-340.
77. Wasilewski M, Disch D, McGill J, et al. Equivalence of shorter course therapy with oritavancin compared to vancomycin cephalexin in complicated skin/skin structure infections. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Chicago: American Society for Microbiology, 2001:UL-18(abst).
78. Zhanel GG, Homenuik K, Nichol K, et al. Glycylcyclines: A comparative review with the tetracyclines. Drugs 2004;64:63-88.
79. Guay DR. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004;24:58-68.
80. Frische TR, Kirby J, Jones RN. Activity of tigecycline tested against 3498 Staphylococcus aureus: Assessment versus community-acquired ORSA. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2004:C2-2000(abst).
81. Stevens T, Johnson B, Johnson J, et al. Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - in vitro antibacterial activity against methicillin-resistant and methicillin-sensitive Staphylococcus aureus isolates. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2004:E-2060(abst).
82. Stevens T, Johnson B, Johnson J, et al. Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - in vitro antibacterial activity against selected species of Enterobacteriaceae. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2004:E-2059(abst).
83. Stevens T, Johnson B, Johnson J, et al. Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - in vitro antibacterial activity against isolates of vancomycin-resistant and sensitive Enterococcus faecium. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004:E-2059 (abst).
84. Goldstein EJC, Citron DM, Merriam CV, et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000;44: 2747-2751.
85. Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-978.
86. Postier RG, Green SL, Klein SR, et al. Results of multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-714.
87. Dartois N, on behalf of the Tigecycline 305 cSSSI Study Group. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2004:L-936 (abst).
88. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). San Francisco: American Society for Microbiology, 1999:416(abst).
89. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49: 1629-1632.
90. Yancey RJ, Sanchez MS, Ford CW. Activity of antibiotics against Staphylococcus aureus within polymorphonuclear neutrophils. Eur J Clin Microbiol Infect Dis 1991;10:107-113.
91. Ong CT, Babalola P, Nightingale CH, et al. Penetration, intracellular accumulation and efflux of tigecycline in human polymorphonuclear neutrophils. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2004:A-1303(abst).
92. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious gram-positive infections. Expert Opin Investig Drugs 2002;12:379-399.
93. Maglio D, Nicolau DP. Antimicrobial Efficacy Review. Infectious Disease Special Edition Annual Clinical Reference. New York: McMahon Publishing Group, 2004:7:33-36.
94. Akins RL, Haase KK, Gram-positive resistance: Pathogens, implications, and treatment options. Soc Infect Dis Pharm Newslett 2004;14:2-7.